MedTrace Logo

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

NCT03769467 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-11-14

Study results available
· View outcomes & findings →

Summary

This is a multicenter, open-label, single-arm Phase 1B/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC).

Conditions

  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Neoplasms
  • Epstein-Barr Virus Infections
  • Epstein-Barr Viraemia
  • Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Interventions

BIOLOGICAL

Tabelecleucel

Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

BIOLOGICAL

Pembrolizumab

pembrolizumab IV infusion

Sponsors & Collaborators

Principal Investigators

  • Aditi Mehta, DO · Atara Biotherapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-19
Primary Completion
2021-08-19
Completion
2021-08-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03769467 on ClinicalTrials.gov